Are there any significant drug interactions between my attention‑deficit/hyperactivity disorder medication (e.g., atomoxetine, methylphenidate, or amphetamine) and omeprazole (Prilosec)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ADHD Medication and Omeprazole (Prilosec) Interactions

There are no clinically significant drug interactions between standard ADHD medications (methylphenidate, amphetamines, or atomoxetine) and omeprazole that require dose adjustments or avoidance of concurrent use.

Stimulant Medications with Omeprazole

Amphetamine-Based Stimulants

  • Lisdexamfetamine (Vyvanse) shows no clinically meaningful interaction with omeprazole. Total drug exposure (AUC and Cmax) remains unchanged when coadministered with omeprazole 40 mg daily 1
  • The median time to peak concentration (Tmax) is identical at 3 hours both with and without omeprazole for lisdexamfetamine 1
  • Only 25% of patients taking lisdexamfetamine showed any shift in Tmax (≥1 hour earlier) with omeprazole, which is not clinically significant 1

Mixed Amphetamine Salts Extended-Release (Adderall XR)

  • Total amphetamine exposure is unaffected by omeprazole, with similar AUC and Cmax values whether taken alone or with a proton pump inhibitor 1
  • However, approximately 50-60% of patients experience an earlier Tmax (median shift from 5 hours to 2.75 hours) when omeprazole is coadministered 1
  • This earlier release occurs because omeprazole's reduction in stomach acid compromises the pH-dependent delayed-release mechanism of the second bead in the extended-release formulation 1
  • Clinical implication: Patients may notice effects sooner in the day but with similar overall symptom control; no dose adjustment is needed 1

Methylphenidate

  • No published pharmacokinetic interaction studies exist between methylphenidate and omeprazole 2, 3
  • Proton pump inhibitors are not listed among medications that significantly alter methylphenidate metabolism or clearance 2, 4
  • Methylphenidate is primarily metabolized by carboxylesterase enzymes, not cytochrome P450 pathways that omeprazole affects 3

Non-Stimulant Medications with Omeprazole

Atomoxetine (Strattera)

  • No interaction is expected between atomoxetine and omeprazole 5, 2
  • Atomoxetine is metabolized primarily by CYP2D6, while omeprazole's main metabolic effects involve CYP2C19 and CYP3A4 2, 4
  • The FDA label for atomoxetine does not list proton pump inhibitors among medications requiring caution or dose adjustment 5
  • Atomoxetine can be taken with or without food, indicating gastric pH does not affect absorption 5

Alpha-2 Agonists (Guanfacine, Clonidine)

  • No documented interactions exist between guanfacine or clonidine and omeprazole 2, 3
  • These medications are not metabolized by pathways affected by proton pump inhibitors 2

Omeprazole's Interaction Profile

  • Omeprazole has the highest potential for drug interactions among proton pump inhibitors due to strong CYP2C19 inhibition and moderate CYP3A4 effects 4
  • However, ADHD medications are not substrates of CYP2C19, the primary enzyme omeprazole inhibits 2, 4
  • Pantoprazole and rabeprazole have lower interaction potential than omeprazole if an alternative proton pump inhibitor is preferred 4

Monitoring Recommendations

  • No additional cardiovascular monitoring is required beyond standard ADHD medication protocols when omeprazole is added 6, 7
  • Continue routine monitoring of blood pressure and heart rate at baseline, after dose increases, and periodically during treatment 6, 5
  • Monitor height and weight in pediatric patients as standard practice for ADHD medications 6
  • For atomoxetine specifically, continue monitoring for suicidality during early treatment phases regardless of omeprazole use 5

Clinical Pitfalls to Avoid

  • Do not reduce ADHD medication doses when starting omeprazole; no pharmacokinetic interaction necessitates adjustment 1, 2
  • If a patient on mixed amphetamine salts extended-release reports earlier onset of effects after starting omeprazole, reassure them this represents altered timing rather than increased total exposure 1
  • Do not confuse the well-documented omeprazole-clopidogrel interaction (which is clinically significant) with ADHD medications, where no such interaction exists 4
  • Avoid attributing ADHD medication side effects to omeprazole interaction; these medications can be safely coadministered 1, 2

Related Questions

Do patients with Attention Deficit Hyperactivity Disorder (ADHD) exhibit varying concentrations of norepinephrine in different brain regions, with some areas having higher and others having lower concentrations?
For a 48-year-old male with combined-type attention-deficit/hyperactivity disorder currently on lisdexamfetamine (Vyvanse) 40 mg taken at 6 am that lasts about 5.5 hours, mild intermittent tachycardia, fragmented sleep, and nightly guanfacine extended-release (Intuniv) 1 mg, should I increase the lisdexamfetamine dose to extend coverage, obtain a sleep study, and continue titrating the guanfacine?
What is the first-line treatment for a patient with inattentive Attention Deficit Hyperactivity Disorder (ADHD)?
In a 36‑year‑old male with attention‑deficit/hyperactivity disorder who has tried methylphenidate, dexmethylphenidate, mixed‑amphetamine salts (Adderall), and serdexmethylphenidate/dexmethylphenidate (Azstarys) but still has problematic ADHD symptoms, what further management is recommended?
What ADHD medication alternatives to amphetamine (Adderall) are appropriate for a 41‑year‑old woman with ADHD who is taking oral acyclovir, topical azelaic acid, weekly semaglutide (Ozempic) for diabetes/weight management, oral spironolactone, and topical tretinoin?
What oral antibiotic regimen is appropriate for a 40-year-old male with a recurrent perirectal abscess after drainage of 10 mL of pus?
How should a newborn with a soft, mobile subcutaneous lipoma and birth‑related Erb’s palsy be evaluated and managed?
Is sodium butyrate an appropriate treatment for suspected increased intestinal permeability (leaky gut)?
What are the concerns and recommended management for a 78‑year‑old male heavy drinker and pipe smoker with hypertension, psoriatic arthritis, and a history of anemia of chronic disease who now presents with mild normocytic anemia, hyponatremia, hypochloremia, and an elevated BUN/creatinine ratio suggesting possible volume depletion?
Do prednisone and other systemic corticosteroids raise blood pressure?
How should a newborn with a soft, mobile subcutaneous mass suspected to be fat necrosis or a lipoma be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.